

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 62113

**Title:** Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?

**Reviewer's code:** 05432362

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-12-29

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2021-09-02 01:07

**Reviewer performed review:** 2021-09-02 02:35

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This report is nicely presented and possesses a clinical value, so I recommend publication after dealing with the following issues, - Please double-check the English language. -Please add one more section about tyrosine kinase inhibitors and their generations in detail. -It should be nice if you can discuss the current approaches used for minimizing nilotinib cytotoxicity. - Please add a conclusion and recommendations.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 62113

**Title:** Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?

**Reviewer's code:** 03434021

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-12-29

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2021-09-04 09:28

**Reviewer performed review:** 2021-09-16 13:22

**Review time:** 12 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

1)Part The main syptom of Nilotinib "A spontaneous decrease.... what does it mean? not clear and should be clarified. 2) Part Nilotinib induced hyperbilirubinemia" It' very disorganised. The authors should clarify their hypothesis in an understandable manner. And should be well organised. 3) Part Conclusion,... noclear enough. Difficult to understand the conclusion . should be clarified and a bit shortened. 4)Page 5, In another case report.... What about the other case reports? what did the authors mean is very confusing. 5) Page 7 Here we report a case ..... What does it mean? When did they report the case? Or do they want to cite an another article? should be clarified. 6) The whole manuscript should be re-evaluated by an experienced author experienced in medical writing

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 62113

**Title:** Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?

**Reviewer's code:** 03434021

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-12-29

**Reviewer chosen by:** Man Liu

**Reviewer accepted review:** 2021-10-18 08:58

**Reviewer performed review:** 2021-10-18 18:30

**Review time:** 9 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors have answered my questions and i think it is now suitable for the publication in the journal. Best regards